Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 19/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5789534 | 0.92 | SLC16A1 (0.78) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL5787985 | 0.91 | SLC16A1 (0.64) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL4804908 | 0.87 | SLC16A1 (0.86) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL5790513 | 0.84 | SLC16A1 (0.67) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL5788286 | 0.83 | SLC16A1 (0.52) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL5786963 | 0.83 | SLC16A1 (0.64) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL5791514 | 0.83 | SLC16A1 (0.68) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL5791248 | 0.82 | SLC16A1 (0.63) | SLC16A1CYP2C9CYP3A4ABCB11 | |
| SCHEMBL5792468 | 0.82 | SLC16A1 (0.67) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 | |
| SCHEMBL3828120 | 0.81 | SLC16A1 (0.66) | SLC16A1CYP2C9CYP3A4ABCB11SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1412362-B1 | THIENO¬2,3-d|PYRIMIDINEDIONES AS INHIBITORS OF T-CELLS PROLIFERATION | ASTRAZENECA AB (SE) | 2006-08-02 | — | — | EP | claimed |